These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37745119)

  • 1. Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction-a substudy of the DAPA-VO
    Mora-Fernández C; Pérez A; Mollar A; Palau P; Amiguet M; de la Espriella R; Sanchis J; Górriz JL; Soler MJ; Navarro-González JF; Núñez J; ;
    Front Cardiovasc Med; 2023; 10():1242108. PubMed ID: 37745119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO
    Palau P; Amiguet M; Domínguez E; Sastre C; Mollar A; Seller J; Garcia Pinilla JM; Larumbe A; Valle A; Gómez Doblas JJ; de la Espriella R; Miñana G; Mezcua AR; Santas E; Bodí V; Sanchis J; Pascual-Figal D; Górriz JL; Baýes-Genís A; Núñez J;
    Eur J Heart Fail; 2022 Oct; 24(10):1816-1826. PubMed ID: 35604416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-Term Changes in Peak VO
    Lorenzo M; Jacobs-Cachá C; Palau P; Amiguet M; Seller J; Núñez E; Espriella R; Górriz JL; Miñana G; Sanchis J; Bayés-Genis A; Soler MJ; Packer M; Núñez J;
    JACC Heart Fail; 2023 Nov; 11(11):1611-1622. PubMed ID: 37676213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction.
    Miñana G; de la Espriella R; Palau P; Amiguet M; Seller J; García Pinilla JM; Núñez E; Górriz JL; Valle A; Sanchis J; Bayés-Genís A; Núñez J;
    Rev Esp Cardiol (Engl Ed); 2023 Oct; 76(10):783-792. PubMed ID: 36958534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction.
    Lorenzo M; Miñana G; Palau P; Amiguet M; Seller J; Garcia Pinilla JM; Domínguez E; Villar S; DE LA Espriella R; Núñez E; Górriz JL; Valle A; Bodí V; Sanchis J; Bayés-Genis A; Núñez J;
    J Card Fail; 2023 May; 29(5):849-854. PubMed ID: 36871614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
    Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
    Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
    Docherty KF; Anand IS; Chiang CE; Chopra VK; Desai AS; Kitakaze M; Verma S; Vinh PN; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Bengtsson O; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Langkilde AM; Jhund PS; McMurray JJV
    JACC Asia; 2022 Apr; 2(2):139-153. PubMed ID: 36339117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible?
    Maltês S; Cunha GJL; Rocha BML; Presume J; Guerreiro R; Henriques C; Rodrigues C; Araújo I; Fonseca C
    Cardiology; 2021; 146(2):201-206. PubMed ID: 33524984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction.
    Amiguet M; Palau P; Domínguez E; Seller J; Pinilla JMG; de la Espriella R; Miñana G; Valle A; Sanchis J; Górriz JL; Bayés-Genís A; ; Núñez J
    Sci Rep; 2023 Jun; 13(1):10591. PubMed ID: 37391470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.
    Yeoh SE; Docherty KF; Campbell RT; Jhund PS; Hammarstedt A; Heerspink HJL; Jarolim P; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Solomon SD; Sjöstrand M; Bengtsson O; Greasley PJ; Sattar N; Welsh P; Sabatine MS; Morrow DA; McMurray JJV
    Circulation; 2023 May; 147(22):1670-1683. PubMed ID: 37039015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
    Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
    Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF.
    Adamson C; Docherty KF; Heerspink HJL; de Boer RA; Damman K; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Petrie MC; Ponikowski P; Sabatine MS; Schou M; Solomon SD; Verma S; Bengtsson O; Langkilde AM; Sjöstrand M; Vaduganathan M; Jhund PS; McMurray JJV
    Circulation; 2022 Aug; 146(6):438-449. PubMed ID: 35442064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial.
    Inzucchi SE; Claggett BL; Vaduganathan M; Desai AS; Jhund PS; de Boer RA; Hernandez AF; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Verma S; Han Y; Kerr Saraiva JF; Bengtsson O; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
    Lancet Diabetes Endocrinol; 2022 Dec; 10(12):869-881. PubMed ID: 36372069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.
    Martinez FA; Serenelli M; Nicolau JC; Petrie MC; Chiang CE; Tereshchenko S; Solomon SD; Inzucchi SE; Køber L; Kosiborod MN; Ponikowski P; Sabatine MS; DeMets DL; Dutkiewicz-Piasecka M; Bengtsson O; Sjöstrand M; Langkilde AM; Jhund PS; McMurray JJV
    Circulation; 2020 Jan; 141(2):100-111. PubMed ID: 31736328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between circulating FGF23, α-Klotho, and left ventricular diastolic dysfunction among patients with preserved ejection fraction.
    Okamoto Y; Fujita S; Morita H; Kizawa S; Ito T; Sakane K; Sohmiya K; Hoshiga M; Ishizaka N
    Heart Vessels; 2016 Jan; 31(1):66-73. PubMed ID: 25223536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial.
    Bergmark BA; Udell JA; Morrow DA; Jarolim P; Kuder JF; Solomon SD; Pfeffer MA; Braunwald E; Sabatine MS
    Eur J Heart Fail; 2019 Apr; 21(4):462-470. PubMed ID: 30773798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients.
    Reis J; Teixeira AR; Gonçalves AV; Moreira RI; Silva TP; Timóteo AT; Ferreira RC
    J Clin Med; 2022 May; 11(10):. PubMed ID: 35629062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eligibility for dapagliflozin in unselected patients hospitalised with decompensated heart failure.
    Kurdi H; Shah P; Barker S; Harris D; Dicken B; Edwards C; Jenkins G
    Br J Cardiol; 2021; 28(2):18. PubMed ID: 35747454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
    Myhre PL; Vaduganathan M; Claggett BL; Miao ZM; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
    JACC Heart Fail; 2022 Dec; 10(12):902-913. PubMed ID: 36114137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.
    Lewis GD; Voors AA; Cohen-Solal A; Metra M; Whellan DJ; Ezekowitz JA; Böhm M; Teerlink JR; Docherty KF; Lopes RD; Divanji PH; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Felker GM
    JAMA; 2022 Jul; 328(3):259-269. PubMed ID: 35852527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.